The primary cause of death in melanoma patients is widespread metastases. Currently, there is no cure in cases of relapse or in advanced stages. A recent article in Science…
St. Jude Children's Research Hospital has recently announced that its team of scientists have established a registry for pediatric melanoma. The goal is to use data from this registry for…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Over the last 50 years, doctors have been working to improve clinical outcomes for patients with a rare but aggressive form of ocular cancer: uveal melanoma. However, there has been…
From April 5 - 30, the American Chemical Society meets to hold ACS Spring 2021, where chemistry professionals meet to discuss new research and knowledge in their field. During the…
First formed and launched within the UPstart incubator at the University of Pennsylvania's Penn Center for Innovation (PCI), biopharmaceutical company Linnaeus Therapeutics, Inc. ("Linnaeus") is now making strides in the…
On March 11, 2021, global biopharmaceutical company Alkermes plc shared that its investigational drug candidate nemvaleukin alfa received Orphan Drug designation from the FDA. The treatment is designed for patients…
Earlier this week, biotechnology company Syntrix Pharmaceuticals ("Syntrix") announced that it had finished dosing all patients in its Phase 1/2 clinical trials. The trials were designed to evaluate SX-682 as a…
According to a recent report in the Journal of Clinical Oncology, over one thousand patients with high-risk stage III melanoma were included in the Keynote-054 clinical trial (NCT02362594). The…
Recently, clinical-stage biopharmaceutical company Aura Biosciences announced a Phase 2 clinical trial to determine the safety, efficacy, and tolerability of AU-011 for patients with choroidal melanoma. Currently, Aura Biosciences…
During the past fifteen years there has been ever-increasing interest in scientific research in the role of microbiome in human health. According to a recent article in Forbes India, this…
A recent Biospace article covers a news release from 4D Pharma in Leeds, England. 4D has announced the first worldwide clinical confirmation of a biotherapeutic product. MRx0518 has been combined…
According to a story from Medscape, the treatment of melanoma, particularly more advanced, metastatic melanoma, has improved significantly over the last couple of decades. Dr. Philip Friedlander says that in…
.jpg)
Pamela Smith, age 67, had run out of options when her melanoma metastasized and became inoperable. According to a recent article in MedicalXpress, in January 2014, Pamela joined the…
According to a story from Healio, data from two studies testing autologous tumor infiltrating lymphocytes (TIL) as a treatment for advanced, metastatic cervical cancer and melanoma suggests that this treatment…
Although some ultrasound and/or CT scan studies may show that patients’ lymph nodes (glands) are free of disease, upon further examination using sentinel lymph node biopsies,(SLNB) the doctors at MD…
An experimental therapy for melanoma patients has shown anti-tumour activity in an ongoing Phase 1 study. The therapy, called pegzilarginase (AEB1102) is being developed by Aeglea BioTherapeutics. For more…
A recent study, carried out by researchers from the National Cancer Institute (part of the NIH) and several other universities, outlines a potential new method of predicting whether immune checkpoint…
The biotechnology company Philogen S.p.A. has announced that the US FDA has awarded Orphan Drug status to Daromun for the treatment of stages IIb to IV melanoma. The original media…
The Melanoma Research Alliance (MRA) and The American Cancer Society (ACS) have announced the first recipients of their new research grants, reports PRNewswire. The grants have been set up as…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
